[Federal Register Volume 67, Number 81 (Friday, April 26, 2002)]
[Notices]
[Page 20828]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-10302]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 28, 2001, Novartis 
Pharmaceuticals Corporation, Attn: Security Department, Building 103, 
Room 335, 59 Route 10, East Hanover, New Jersey 07936, made application 
by renewal to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of methylphenidate (1724), a basic 
class of controlled substance listed in Schedule II.
    The firm plans to manufacture finished product for distribution to 
its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than June 25, 2002.

    Dated: April 11, 2002.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 02-10302 Filed 4-25-02; 8:45 am]
BILLING CODE 4410-09-M